Amgen calls Colorado’s price controls on Enbrel ‘unconstitutional’

Amgen on Monday called on a Colorado federal court to overturn the state drug affordability board’s decision to cap the price of Amgen’s blockbuster biologic Enbrel.

The California-based company said Colorado’s price controls are “unconstitutional for at least four reasons,” including that the state board does not provide “any meaningful…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks